The 2014 Euro-GASP AMR data for each country (n = 19) were weighted to account for differences in the distribution of patient characteristics between Euro-GASP and EU/EEA epidemiological gonorrhoea surveillance data.
Thus, the RU-GASP can be considered a successful gonorrhea surveillance program, and the current state of <i>N. gonorrhoeae</i> antimicrobial resistance in Russia is less serious than that in other WHO GASP regions.